Supriya Lifescience Reports Q2 Results and Appoints Mangesh Vaze as COO
Supriya Lifescience Ltd · Change in Management · 06 Nov 2026, 6:46 pm
Supriya Lifescience Reports Q2 Results and Appoints Mangesh Vaze as COO Supriya Lifescience reported standalone revenue from operations of ₹2,062.97 million for the quarter ended 30th Sep'26, up 3.2% YoY from ₹1,998.33 million and 8.7% QoQ. Net profit declined 42.0% YoY to ₹292.50 million versus ₹504.27 million in the year-ago period, but rose 21.7% QoQ from ₹240.43 million. H1 FY27 revenue reached ₹3,960.44 million with a net profit of ₹532.93 million. Additionally, the Board appointed Mangesh Vaze as Chief Operating Officer and Senior Management Personnel, effective 6th Nov'26.
Original exchange filing (PDF)
More announcements from Supriya Lifescience Ltd
- Earnings Call Transcript is enclosed herewith. · 13 Nov 2026
- Outcome of the Results Earning Call for Quarter and Half year ended September 30, 2026 is enclosed herewith. · 07 Nov 2026
- Press Release is enclosed herewith. · 07 Nov 2026
- Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026. · 06 Nov 2026
- Please find enclosed. · 06 Nov 2026
- Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 06 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held .... · 06 Nov 2026
- Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record. · 03 Nov 2026
